Biggest News Aggregation in the World
📰 Upfront Payment News

Page 6 - Upfront Payment News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Upfront Payment. Real-time updates on events, politics, business and more.

Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products

Acquisition Advances Kamada’s Strategy of Evolving Into a Fully-Integrated Specialty Plasma Company with Strong Commercial Capabilities in the U.S.; Kamada’s Wholly-Owned U.S. Subsidiary, Kamada Inc, will be Responsible for the Commercialization of the Products in the U.S. Market.
United States City Of United Kingdom Distribution Network Amir Co Kamada Ltd

Investegate |MorphoSys AG Announcements | MorphoSys AG: MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma

Investegate announcements from MorphoSys AG, MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
United States United Kingdom Million Development Funding Bonds Development Funding Bonds Strategic Funding Partnership Constellation Pharmaceuticals Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma

MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) ("Constellation") whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billio...
United States United Kingdom Julia Neugebauer Novarti Promacta Myles Clouston Merck Januvia

Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies

Share: Allogene Overland Biopharm, a First-of-its-Kind Collaboration in Allogeneic Cell Therapy, Is Dedicated to Making AlloCAR T™ Available to Patients in Greater China, Taiwan, South Korea and Singapore The Joint Venture Provides An Opportunity to Accelerate the Global Development of AlloCAR T Therapies for Hematologic Malignancies and Solid Tumors Overland, Backed by Hillhouse Capital, to Invest $117 Million in Capital, Which Includes an Upfront Payment to Allogene and Financial Support to...
United States South Korea Madeline Davidshofer Biopharm Allogene Christine Cassiano David Chang

Detailed text transcripts for TV channel - MSNBC - 20110419:11:24:00

>> weve gotten some claims from dentists, kai proprak tors, veterinarians. but i want to emphasize most of the claims in the gulf are for real people. i dont want to make a joke of this. fishermen, shrimpers, oyster harvesters, hotels right on the beach. thats where the $4 billion has gone. and im determined. you know, you take a lot of heat on this, but im determined to process these claims and get money out the door to eligible claimants. >> you know, ken, as you know, im from pensacola. a lot...
Oyster Harvesters Kai Proprak Tors Isn T On The Beach 4 Billion Ken Feinberg

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science